In a randomized, controlled trial involving patients with membranous nephropathy, rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and ...

Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes. The combination regimen rituximab ...

Please provide your email address to receive an email when new articles are posted on . The addition of copanlisib to rituximab increased response rates and significantly extended PFS among patients ...

Abstract Number: PB3180 About the study The triple combination arm in the ongoing Phase 2a study combines the subcutaneous formulation of BI-1206 and rituximab with Calquence ® (acalabrutinib) in ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors. The initial ...

Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or ...